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An investigation of BMP-7 
mediated alterations to BMP 
signalling components in human 
tenocyte-like cells
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Karen Ruschke4, Regina Puts1,3, Petra Knaus3,4 & Britt Wildemann1,2
The incidence of tendon re-tears post-surgery is an ever present complication. It is suggested that 
the application of biological factors, such as bone morphogenetic protein 7 (BMP-7), can reduce 
complication rates by promoting tenogenic characteristics in in vitro studies. However, there remains 
a dearth of information in regards to the mechanisms of BMP-7 signalling in tenocytes. Using primary 
human tenocyte-like cells (hTLCs) from the supraspinatus tendon the BMP-7 signalling pathway 
was investigated: induction of the BMP associated Smad pathway and non-Smad pathways (AKT, 
p38, ERK1/2 and JNK); alterations in gene expression of BMP-7 associated receptors, Smad pathway 
components, Smad target gene (ID1) and tenogenic marker scleraxis. BMP-7 increases the expression 
of specific BMP associated receptors, BMPR-Ib and BMPR-II, and Smad8. Additionally, BMP-7 activates 
significantly Smad1/5/8 and slightly p38 pathways as indicated by an increase in phosphorylation and 
proven by inhibition experiments, where p-ERK1/2 and p-JNK pathways remain mainly unresponsive. 
Furthermore, BMP-7 increases the expression of the Smad target gene ID1, and the tendon specific 
transcription factor scleraxis. The study shows that tenocyte-like cells undergo primarily Smad8 and 
p38 signalling after BMP-7 stimulation. The up-regulation of tendon related marker genes and matrix 
proteins such as Smad8/9, scleraxis and collagen I might lead to positive effects of BMP-7 treatment for 
rotator cuff repair, without significant induction of osteogenic and chondrogenic markers.
High rates of re-tears or non-healing represent the common complications after surgical intervention to repair 
the rotator cuff tendons. Modified suture techniques, aimed at improving tendon strength after surgical repair 
have not resulted in distinctly better tendon healing outcomes for the patients1,2. There is a point of view that 
the investigation and optimisation of biological treatment strategies will reduce future rates of re-tears and 
non-healing post-surgery. One such biological strategy would be the application of growth factors, such as bone 
morphogenetic protein-7 (BMP-7), to improve the healing outcome after tendon surgery. The in vitro application 
of BMP-7 to tenocytes improved cell activity, and the expression and synthesis of extracellular matrix proteins 
such as collagen-I and III, without enhanced expression of collagen-II and osteocalcin3–9.
BMP-7 functions through the binding to specific BMP transmembrane receptors at the cell surface. These 
specific BMP-receptors (BMPRs) are classified into two groups, BMPR type I and BMPR type II, and conduct 
BMP signalling through the formation of a heterotetrameric complex comprised of two receptors of BMPR type I 
and BMPR type II each10,11. The BMPR type I receptors: BMPR-1a, BMPR-1b and ActR-1; and the BMPR type II 
receptors: BMPR-II: ActR-IIa and ActR-IIb have been shown to be associated with BMP-7 signalling12.
Activated receptors induce intracellular signalling through Smad and/or Smad-independent pathways 
(phosphoinositide-3-kinase (PI3K)/ protein kinase B (Akt) pathway, the Jun nuclear kinase (JNK)/p38 pathway 
and the extracellular signal regulated kinase (ERK))13.
The Smad pathway is initiated by binding of a BMP molecule to the receptor complex resulting in a phospho-
rylation of the receptor regulated Smad1/5/8 (rSmads). The phosphorylated rSmads are released to the cytoplasm 
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as a dimer and/or trimer to form a complex with the mediator Smad4 (co-Smad4). This Smad complex trans-
locates into the nucleus, where it activates the transcription of target genes, e.g. inhibitor of differentiation 1 
(ID1)14,15. On the other hand the Smad-independent pathways are activated by phosphorylated BMP bound 
receptor complex12 and act via Akt16,17, Erk1/218,19, p3820,21, JNK18,22 and Rho/ROCK23 pathways.
BMP signalling mechanisms are well studied and vary depending on the BMP ligand and on the cell type. 
To date, no detailed BMP-7 signalling analysis regarding receptors, signalling molecules and target genes was 
performed in human tenocytes, which is to be addressed in this present study. An improved understanding of 
BMP signalling mechanisms in tenocytes may open opportunities to use this growth factor for future treatment 
strategies to improve tendon healing.
Results
Basal gene expression level of tenocyte-like cells. Primary human tenocyte-like cells (hTLCs) were 
isolated from the supraspinatus tendon from six male donors (62–67 years, Goutallier grade 1 or 2). Gene expres-
sion was evaluated by quantitative real time polymerase chain reaction (qRT-PCR). All hTLCs expressed tenocyte 
markers or typical proteins such as scleraxis, mohawk, collagen I, and aggrecan, whereas the osteogenic makers 
Runx2 and osterix were not expressed and osteocalcin only to a lesser extent. Collagen II as the main ECM com-
ponent of cartilage was not expressed and Sox9 only in very small amounts (Table 1).
Basal gene expression level of BMP receptors and Smads in untreated hTLCs. The basal gene 
expression level of the type I receptors showed the strongest presence of BMP receptor (BMPR)-Ia, closely fol-
lowed by Activin receptor (ActR)-I in the tenocyte-like cells (TLCs). BMPR-Ib was expressed in lower amounts. 
In the type II receptor group, BMPR-II was expressed in high amounts, while ActR-IIa and ActR–IIb showed 
weaker expression. The receptor regulated Smad5 was expressed in high amounts followed by Smad8 and 1 
(Table 1).
BMP receptor expression in hTLCs after BMP-7 stimulation. The hTLCs were treated for 1, 2, 4 and 
8 hours with two concentrations of BMP-7 (200 ng/ml and 1000 ng/ml). Of the type I receptor group, BMPR-Ia 
expression was significantly increased from 2 hours after low (200 ng/ml) and high (1000 ng/ml) BMP-7 stimu-
lation compared to untreated control (200 ng/ml BMP-7 at 2 h: p = 0.015, others: p = 0.002, Fig. 1A). Expression 
of BMPR-Ib showed the strongest regulation, which was significantly up-regulated at 8 hours stimulation with 
a 4.8-fold at the high and 2.5-fold at the low BMP-7 concentration compared to control (all p = 0.002, Fig. 1B). 
The ActR-I expression increased significantly after 2 hours of stimulation at the high concentration of BMP-7 (all 
p = 0.002, Fig. 1C).
Of the type II BMP receptors: BMP-7 stimulation induced the strongest increase to BMPR-II gene expression. 
Expression increased significantly from 2 hours, to reach a maximum increase at 8 hours of 5.3-fold at high con-
centration, and 2.5-fold for the low concentration (all p = 0.002, Fig. 2A). ActR-IIa expression was slightly but 
significantly increased at 1, 2, 4 hours of stimulation (200 ng/ml BMP-7: p = 0.03, others: p = 0.004, Fig. 2B) but 
no increase was measured at 8 hours. The ActR-IIb gene expression significantly decreased 2 and 4 hours after 
stimulation in both concentrations of BMP-7 compared to the unstimulated control (all p = 0.002, Fig. 2C).
Phosphorylation of Smad1/5/8 in hTLCs stimulated with BMP-7. The C-terminal phosphorylation 
of Smad1/5/8 in hTLCs after 15, 30, 60 or 120 minutes of BMP-7 stimulation was determined by the use of phos-
phorylation state-specific antibodies. Quantification was achieved when normalising the signal to total Smad1 
and GAPDH. BMP-7 induced significant phosphorylation of Smad 1/5/8 after 30 and 60 min of stimulation (all 
p = 0.002) and the signal declined again at 120 min (Fig. 3).
Regulation of Smad expression in response to BMP-7 stimulation in hTLCs. To determine if 
BMP-7 is inducing alterations in expression of main signalling components the gene expression of receptor reg-
ulated Smad1, 5, 8 and the co-Smad4 in the hTLCs was investigated. The expression of the receptor regulated 
Smad1 was significantly elevated at 4 hours after stimulation by both BMP-7 concentrations (all p = 0.002), while 
Smad5 expression was not altered (Fig. 4A,B). The expression of the receptor regulated Smad8 (whose gene is 
called Smad9) increased significantly at later stimulation times (4 and 8 hours) with a maximum increase of 
around 3-fold compared to the untreated control (all p = 0.002, Fig. 4C). The co-Smad4 expression was slightly 
increased over most stimulation times (all p = 0.002, Fig. 4D).
Tenogenic marker Osteogenic marker Chondrogenic marker
Mohawk Scleraxis Collagen I Osteo calcin Runx2 Osterix Aggrecan Sox9 Collagen II
Median 26.81 27.39 19.12 31.41 n.d. n.d. 23.76 34.14 n.d.
1.-3. quartile 26.32–27.60 27.16–28.59 18.29–19.32 30.84–31.93 23.35–25.74 33.50–34.94
Type I receptors Type II receptors R-Smads
BMPR-Ia BMPR-Ib ActR-I BMPR-II ActR-IIa ActR-IIb Smad1 Smad5 Smad8
Median 26.49 31.52 27.41 25.23 34.53 31.69 28.84 26.58 28.45
1.-3. quartile 26.22–26.95 30.79–32.16 27.12–27.80 25.04–25.67 33.62–36.08 31.01–32.18 28.56–29.17 26.29–26.92 28.06–28.88
Table 1.  Basal gene expression levels (CT-values) of unstimulated hTLCs.
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Non-Smad signalling induction by BMP-7 in hTLCs. Phosphorylated non-Smad signalling proteins, 
i.e. Erk1/2, p38, JNK and AKT were evaluated in 3 exemplary hTLCs after BMP-7 stimulation. A slight increase 
in the level of phosphorylated p38 was seen after 15 minutes of BMP-7 (200 nM) stimulation and was increased 
after 60 and 120 minutes with both concentrations. BMP-7 induced an increase in phosphorylated AKT after 
30–120 minutes. Phosphorylated ERK1/2 was abundant in high concentration independent of the stimulation 
and p-JNK proteins were not upregulated (Fig. 5).
Target gene expression in hTLC. The Inhibitor of Differentiation 1 (ID1) is a primary target gene in the 
Smad-signalling pathway. Stimulation of hTLC with BMP-7 significantly increased the ID1 expression compared 
to the untreated control with a maximum increase of 10.7-fold in the high and 9.2-fold in the low BMP-7 dose 
group at 8 hours of stimulation (all p = 0.002, Fig. 6A). The expression of the tendon related transcription factor 
scleraxis significantly increased over the entire stimulation period reaching a maximum increase of 13.3-fold for 
the high and 8.5-fold for the low concentration group at the late time point (all p = 0.002, Fig. 6B).
Figure 1. Gene expression of BMP type I receptors in response to BMP-7. Box plots represent qRT-PCR 
results given as mean normalised expression relative to 18S rRNA and the untreated control (reference line) 
using an efficiency corrected formula (n = 6). Symbols indicate statistically significant differences to the 
untreated control. (A) BMPR-Ia expression was increased after 2 to 8 h of BMP-7 stimulation (#p = 0.015, 
* p = 0.002). (B) BMPR-Ib expression was highly increased after 4 and 8 h of stimulation compared to 
unstimulated control (* p = 0.002). (C) ActR-I expression was increased at 2 h to 8 h with a peak at 4 h in the 
high BMP-7 group (* p = 0.002).
Figure 2. Gene expression of BMP type II receptors in response to BMP-7. Box plots represent qRT-
PCR results given as mean normalised expression relative to 18S rRNA and the untreated control (reference 
line) using an efficiency corrected formula. Symbols indicate significant differences to the untreated control 
(n = 6). (A) BMPR-II expression was strongly increased after 2 to 8 h of BMP-7 stimulation which was more 
pronounced in the high BMP-7 group (* p = 0.002. (B) The expression of ActR-IIa was increased in the low 
BMP-7 group after 1 h, in the high BMP-7 group after 2 h and 4 h after stimulation by both concentrations 
(#p = 0.03, * p = 0.004). (C) ActR-IIb expression was significantly down regulated after 2 h and 4 h compared to 
the untreated control (* p = 0.002).
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Pathway inhibition experiments showed that the enhancing effect of BMP-7 on the expression of ID-1 and 
scleraxis can be reversed by LDN-193189 (inhibitor of Smad-pathway) and PD169316 (inhibitor of p38-pathway) 
but not by the AKT-inhibitor (Fig. 7).
To examine whether the BMP-7 stimulation of the hTLCs might alter the tenogenic to an osteogenic or chon-
drogenic phenotype, the expression of the tenocyte markers scleraxis, mohawk and the main matrix protein 
collagen I was again tested after 8 h of stimulation as well as osteocalcin, osterix, Runx2 (osteogenic marker) and 
Sox9, collagen type II, and aggrecan (chondrogenic marker or matrix proteins). The expression level of mohawk, 
which was highly expressed already in the untreated control, did not change after the BMP-7 stimulation, whereas 
collagen I (1.5-fold) and scleraxis (7.5-fold, p = 0.008) level increased. Runx2 and osterix expression could not 
be observed in the tenocyte cultures and osteocalcin expression was weak. Furthermore, collagen II expression 
was not detectable, the expression level of aggrecan did not change, and only Sox9 was slightly upregulated after 
BMP-7 stimulation (Fig. 8).
Discussion
As unsatisfactory healing outcomes post tendon surgery remains a severe clinical complication, it is necessary to 
investigate the application of growth factors as treatment option for improved tendon regeneration. The growth 
factor BMP-7 can be considered a candidate factor as previous studies have shown that it is capable of inducing 
proliferation and collagen-I synthesis of cells from tendons and ligaments3–9. It is the aim of this study to further 
investigate BMP-7 signalling in tenocytes through the analysis of the signalling components in human tenocyte 
like cells (hTLCs) in the presence of BMP-7.
The present study shows for the first time that BMP-7 leads to an increase in phosphorylation of rSmads 
in hTLCs. The phosphorylated rSmad should complex with the co-Smad4, translocate into the nucleus and 
increase the expression of the transcription of ID1 (a canonical target gene in BMP signalling) and the tendon 
related transcription factor scleraxis. An increase of the gene expression of the rSmad component, Smad8, but 
no change amongst its Smad1/5 and co-Smad-4 partners is observed. Furthermore, the receptors BMPR-Ib and 
BMPR-II gene expression is strongly increased in hTLCs in the presence of BMP-7. Taken together this could be 
indicative of BMP-7 selecting a pool of signalling components (receptors and intracellular components) that are 
pro-tenogenic.
Different BMP ligands were shown to have different affinities for different BMP receptors. While BMP-2 pref-
erentially binds to BMPR-Ia and –Ib and less to BMPR-II24,25, BMP-7 has high affinity for ActR-I, BMPR-Ib, and 
to a lesser extent BMPR-Ia10,11. BMPs have a general lower affinity for type II receptors. However, it was shown 
that BMP-7 also binds to BMPR-II, ActR-IIa, and ActR-IIb26–29. In COS-1 cells stimulated with BMP-7 BMPR-II 
has been shown to preferentially complex with ActR-I and to a lesser extent with BMPR-Ia and-Ib28. As the 
present study investigated mRNA expression levels of BMP receptors, further research needs to be carried out to 
investigate the receptor complex preferences of BMP-7 in hTLCs. Based on our data, showing a strong increase 
in BMPR-Ib and BMPR-II expression after BMP-7 stimulation, we speculated that this may increase the presence 
of these receptors on the cell surface and therefore increases the likelihood of BMP-7 binding a BMPR-Ib and 
BMPR-II receptor complex on hTLCs.
The receptor regulated Smads1/5/8 are phosphorylated through the activation of type I receptors30, which 
could possibly be BMPR-Ib in the present study. The western blot analysis showed BMP-7 stimulation of hTLCs 
leads to the phosphorylation of Smad1/5/8, strongly suggesting BMP-7 induces the Smad signalling cascade. 
The phosphorylation analysis was not able to distinguish between the three receptor-associated Smads, but the 
expression analysis showed a strong increase of Smad8 expression in the hTLCs, whereas, Smad1 was only slightly 
increased and Smad5 was not affected. This leads us to consider that Smad8 may be a prominent signalling mol-
ecule in hTLCs in response to BMP-7 treatment. This assumed preference of Smad8 signalling in the hTLC is 
supported by previous studies showing that Smad8 plays an important role in tenogenic differentiation31,32. It 
Figure 3. Phosporylation of Smad1/5/8 after BMP-7 stimulation. (A) Exemplary western blots show 
increased Smad 1/5/8 phosphorylation after 30 and 60 min of stimulation with BMP-7, but no increase in total 
Smad1 levels compared to unstimulated controls. GAPDH serves as reference protein. Imaging was conducted 
using the Odyssey imager and LiCor Odyssey software. (B) Quantification of relative phosphorylation 
normalised to total Smad1 and GAPDH was significantly increased at 30 and 60 min (n = 6). Stars mark 
significant differences to the untreated control, p = 0.002.
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was demonstrated that Smad8 is able to induce tenogenic differentiation, while suppressing chondrogenic and 
osteogenic differentiation in a murine MSC cell line (C3H10T1/2) and furthermore promoted tendon formation 
in a rat Achilles tendon model31. In contrast, Smad1 and 5 were reported to induce osteogenic differentiation in 
C2C12 cells33 and C3H10T1/2 cells31,34. While the Smad1/5/8 are highly conserved: maintaining a three domain 
structure (MH1. MH2 separated by a linker region), the key divergence between Smad1/5 and Smad8 is found 
within the linker region35–37. The linker region plays an important role in post-translational modification, such 
as phosphorylation38. A previous study has shown that BMP-2 induces Smad1 and 5 phosphorylation as well as 
osteogenic differentiation in human tendon cells39. However, Smad1 and 5 were only weakly regulated in the pres-
ent study, we surmise, osteogenic differentiation might not occur after BMP-7 stimulation. This is also supported 
by the unchanged osteocalcin expression in this and previous studies3–5. Hoffmann et al. clearly showed that 
BMPR-Ib strongly increases the phosphorylation of Smad8 as compared with other BMPR type I receptors31. This 
would be in line with the present findings of a strongly increased BMPR-Ib expression together with a strongly 
up-regulated Smad8 expression. A recently published study investigated the role of Smad1, Smad5, and Smad8 in 
BMP signalling and concluded that Smad8 has a unique action compared to the other two Smads40. After activa-
tion of the BMP signalling, Smad8 expression was increased in C2C12 cell line resulting in a reduced BMP activ-
ity. This present study also demonstrates an increased Smad8 expression but not a reduction in the BMP-activity 
after BMP stimulation was seen in the tenocyte-like cells.
Figure 4. Gene expression of Smad1, 5 and 8/9 and co-Smad4. Box plots represent qRT-PCR values given as 
mean normalised expression relative to 18S rRNA and the untreated control (reference line) using an efficiency 
corrected formula (n = 6). Stars indicate significant differences to the untreated control. (A) Expression of 
Smad1 was increased only at 4 h of BMP-7 stimulation (* p = 0.002). (B) Smad5 expression was not regulated 
compared to unstimulated control. (C) Smad8/9 expression increased after 4 h in the high BMP-7 group and 
highly increased after 8 h in both concentrations (* p = 0.002). (D) Smad4 expression was slightly increased after 
1, 4 and 8 h of stimulation (* p = 0.002).
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In the present study, the co-Smad4 expression was slightly increased; indicating the possibility of the forma-
tion of a Smad complex in hTLCs after BMP-7 stimulation. This complex could translocate into the nucleus to 
activate the transcription of target genes. One of the target genes is ID1, a helix loop helix protein41, which expres-
sion was significantly increased by BMP-7 in the present study. The strong increase in ID1 expression, which 
is significantly reduced after inhibition of the Smad-pathway, furthermore underlines the utilisation of Smad 
signalling in the hTLCs after BMP-7 stimulation.
Our examination of the non-Smad signalling components in hTLCs in the presence of BMP-7 has shown: an 
increase of phosphorylated p38; a slight increase of phosphorylated Akt; while phosphorylated ERK1/2 and JNK 
remained mainly unaltered, except for a significant downregulation of pERK after 15 minutes. Due to the fact 
that only three samples were analysed, the statistic is not very strong and we would not interpret this as a dra-
matic effect. From this we surmise BMP-7 preferentially selects the p38 signalling pathway compared to the other 
non-Smad pathways investigated in this study. This is supported by the reduced ID1 expression after inhibition 
Figure 5. Phosphorylation of non-Smad signalling molecules. (A) Exemplary western blots show increased 
p38 phosphorylation after 60 and 120 min. p-AKT was slightly increased after 120 min. No regulations were 
visible for p-Erk1/2 and p-JNK. Beta actin and GAPDH served as reference proteins. Imaging was conducted 
using the Odyssey imager and LiCor Odyssey software. (B) Quantification of 3 independent western blots 
(mean ± SD). Bands from the protein of interest were normalised to β -Actin or GAPDH and the unstimulated 
control, * p = 0.003, #p = 0.031, compared to control.
Figure 6. Gene expression of BMP target gene ID1 and tendon marker scleraxis. Box plot graphs represent 
qRT-PCR values given as mean normalised expression relative to 18S rRNA and the untreated control (reference 
line) using an efficiency corrected formula (n = 6). Stars indicate significant differences to the untreated control. 
(A) ID1-expression was significantly increased at all concentrations and time points with the strongest increase at 
8 h compared to the unstimulated control (* p = 0.002). (B) The expression of scleraxis was up-regulated at both 
concentrations for all time points and showed the strongest increase after 8 h of BMP-7 stimulation (* p = 0.002).
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of the p38 kinase. These results are in accordance with a study from Fiori et al. demonstrating that the inhibition 
of p38 results in a reduced ID1 expression after BMP-4 stimulation, whereas inhibition of ERK or JNK had no 
effect42.
Despite previous studies having associated BMP-7 with the PI3K/Akt pathway16,17, it is inconclusive from our 
data if BMP-7 leads to Akt phosphorylation. Different studies found PI3K/Akt to have paradoxical roles in both: 
promoting43 and inhibiting44,45 osteoblastic differentiation. The BMP-7 induced inhibition of osteoblastic differ-
entiation is mediated through induction of PI3K/Akt and could aid cell decision making towards a tenogenic 
outcome; essential to the promotion of tendon healing.
It is still a matter of discussion whether BMP-7 positively or negatively affects tendon healing. On one hand, 
BMP-7 has been described to have a negative effect on tendon healing by inducing bone formation46. The hTLCs 
in this study, however, showed no increase in osteogenic factors after stimulation with BMP-7. Only Sox9, a 
high-mobility group box-containing transcription factor functioning as a key regulator of chondrogenesis, was 
upregulated after 8 h stimulation. In a cell culture study, overexpression of Sox9 in tenocytes led to a switch of the 
cell profile towards the chondrogenic lineage, accompanied by a downregulation of scleraxis and an upregulation 
of type II collagen and Chondromodulin-I47. In contrast, in the present study scleraxis was significantly upreg-
ulated and collagen II was not detectable at all indicating no chondrogenic differentiation after stimulation with 
BMP-7. On the other hand, positive effects of BMP-7 were already reported in the promotion of tendon repair48. 
Further evidence that BMP-7 has positive effects on tendon repair has been postulated in several cell culture 
studies, which revealed BMP-7 enhanced cell proliferation and Col-I expression of ligament and tendon cell 
cultures3–9. Lui et al. described BMP/Smad signalling to be related to tendinopathy as investigated in a rat tendon 
injury model, however, BMP-7 and BMPR-II seem to have lesser involvement49. Furthermore, BMP-7 is shown 
to be intensely expressed in the developing flexor tendon50 and is found in ovine tendon-bone healing51. These 
positive findings are further underlined by this present study showing a strongly increased scleraxis expression 
in hTLCs after BMP-7 stimulation. Scleraxis is a basic-helix-loop-helix transcription factor that plays an impor-
tant role in tendon development and differentiation52,53. For example, scleraxis can regulate the expression of the 
glycoprotein tenomodulin, which acts as another important tendon marker54,55. Tenomodulin is key to collagen 
fibril maturation and its loss in vivo leads to loss of tendon density, this may indicate the essential role of scleraxis 
for a proper tendon healing outcome and supports the assumption that BMP-7 might be a good treatment option 
for tendon repair. This assumption is underlined by previous studies of the group showing an increased cell pro-
liferation and collagen expression and synthesis of tenocytes (mostly independent on donor characteristics such 
as age, sex, degeneration) after stimulation with BMP-7 for several days3–5.
Conclusion
This present study shows that BMP-7 signalling of hTLCs, isolated from human supraspinatus tendons (donors: 
male, 62–67 years, Goultallier grade 1–2), operates primarily through the Smad pathway and to less extend 
through the p38 pathway, leading to the increase of the tendon markers and matrix proteins such as Scleraxis, 
Collagen I, and aggrecan but not osteogenic and only slightly Sox9 as a chondrogenic marker. Considering these 
points at the cellular perspective, BMP-7 seems to be a promising growth factor for the augmentation of tendon 
healing in clinics. It is interesting to note that BMP-7 induces a selective increase of BMP signalling components: 
Figure 7. Inhibition of intracellular pathways, gene expression of BMP target gene ID1 and tendon marker 
scleraxis. Box plot graphs represent qRT-PCR values given as mean normalised expression relative to 18S 
rRNA and the untreated control (reference line) using an efficiency corrected formula (n = 3). Inhibitors for the 
specific pathway were used in two concentrations. The inhibition of the Smad-pathway by LDN-193189 (LDN) 
resulted in a significant reduction of ID1 and scleraxis expression, less reduction was seen after inhibition of the 
p38 pathway with PD169316 (PD) and no effect after inhibition of the Akt-pathway (Akt), * p < 0.003, #p < 0.04, 
compared to BMP-7.
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BMPR-II, BMPR-Ib, and Smad8. The detailed analysis of the canonical and non-canonical signalling pathways 
suggests that BMP-7 supports the tenogenic phenotype, which is mediated primarily through Smad8 and to less 
extend through p38 associated pathways, without induction of osteogenic or chondrogenic phenotype.
Material and Methods
Cell culture. HTLCs of torn supraspinatus tendon biopsies were isolated from 6 male donors (62–67 years, 
Goutallier grade 1 or 2), undergoing arthroscopic or open shoulder surgery. Biopsies were obtained 3 to 5 mm 
from the torn proximal tendon edge. All patients gave their written informed consent. The tissue harvest was 
carried out in accordance with the local guidelines of the Charité-Universitätsmedizin Berlin and the study was 
approved by the ethics committee of the Charité-Universitätsmedizin Berlin (Ethic number: EA1/060/09).
HTLCs were isolated from SSP tendon biopsies by collagenase digestion (0.3% collagenase type CLS II) as 
described previously56. Cells were cultured with normal growth medium (Dulbecco’s Modified Eagle Medium 
(DMEM)/Ham’s F12 with 10% fetal calf serum (FCS) and 1% Penicillin/Streptomycin (P/S), all Biochrom AG. 
Germany) at 37 °C, with 95% humidity and 5% carbon dioxide, with a medium change three times per week.
BMP-7 stimulation. Human tenocyte like cells (hTLCs) at passage 1 were thawed and cultured for 1 week 
prior the trypsinisation and then seeded in 35 mm petri dishes at a density of 4.5 × 104 vital cells. The cells were 
cultivated for 3 days in the dishes until BMP-7 stimulation (rhBMP-7, R&D Systems GmbH, Germany). Medium 
was removed and medium without FCS was added and incubated for 3 h at 37 °C for starvation. Starving medium 
was removed and fresh starving medium supplemented with 200 or 1000 ng/ml rhBMP-7 was applied to the cells. 
The concentration is based on previous experiments6. After 15, 30, 60 and 120 min cells were lysed in 200 μ l 1x 
Laemmli buffer (62.5 mM Tris HCl. 7.5% glycerol, 2.1% β -mercaptoethanol, 4.2% SDS. 0.01% bromphenolblue) 
and stored at − 20 °C until used for Western Blot analysis. After 1, 2, 4 and 8 h RNA was isolated from the cells 
using the NucleoSpin RNA Kit (Macherey Nagel, Germany) for gene expression analysis by quantitative real-time 
polymerase chain reaction (qRT-PCR). Each experiment was made with n = 6 tenocyte cultures per group and 
time point.
To characterise changes in the cell phenotype after BMP-7 stimulation qRT-PCR was performed at the end of 
the stimulation experiment (time point: 8 h) for markers of tenocytes (scleraxis, mohawk, and collagen I), osteo-
cytes (osteocalcin, osterix, and Runx2) and chondrocytes (Sox9, collagen II, and aggrecan) and compared to the 
unstimulated control.
Inhibition experiments were performed to clarify which intracellular pathways are actively induced by BMP-7 
in tenocytes. Three different inhibitors were used having different effects on the Smad- and non-Smad pathways. 
LDN193189 (Cayman, USA), which was added in a concentration of 1 μ M and 5 μ M, inhibits SMAD1/5/8 phos-
phorylation by the BMP- type I receptors. Akt-inhibitor (Calbiochem, USA) is a selective inhibitor of the protein 
kinase B (AKT) (used concentration: 5 μ M and 10 μ M) and PD169316 (Cayman, USA) selectively inhibits p38 
MAPK (used concentration: 5 μ M and 10 μ M). Tenocytes were starved for 3 h, the inhibitors added during the 
last starving hour, followed by a stimulation with BMP-7 (200 ng) and the inhibitors in different concentrations 
for further 8 hours. At the end of the experiment RNA was extracted and qRT-PCR performed. The experiments 
were performed in triplicates.
qRT-PCR. RNA quantity and purity was analysed with Nanodrop ND-1000 Spectrophotometer (PeqLab 
Biotechnologie, Germany). A total of 100 ng RNA were transcribed into complementary DNA (cDNA) using the 
Figure 8. Gene expression of tenogenic, osteogenic, and chondrogenic markers to evaluate cell phenotype 
after BMP-7 stimulation. Box plot graphs represent qRT-PCR values given as mean normalised expression 
relative to 18S rRNA and the untreated control (reference line) using an efficiency corrected formula (n = 6). 
Stars indicate significant differences to the untreated control. After 8 h of BMP-7-stimulation hTLCs expressed 
significantly higher amounts of the tenogenic markers scleraxis (p = 0.008) and matrix protein collagen I, 
whereas osteogenic markers were not upregulated or not expressed at all (Runx2 and osterix) and only Sox9 was 
upregulated as a marker for chondrogenic differentiation.
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qScript cDNA Supermix (Quanta BioSciences. USA) with the Epgradient Mastercycler (Eppendorf. Germany). 
PCR was performed using 1.25 ng cDNA and the Sybr Green Mastermix (Quanta BioSciences). All primer 
sequences were designed using Primer 3 software (Freeware; http://frodo.wi.mit.edu/primer3) and were pro-
duced by Tib Molbiol, Germany (Primer sequences see Table 2). The CT value of the gene of interest was nor-
malised to the CT of the housekeeping gene 18S ribosomal RNA and the primer efficiency was included in the 
calculation to optimise the validity of results57. The mean normalised expression (MNE) was calculated according 
to the following formula (Equation 1):
=MNE s Efficiency
Primer Efficiency
18 s CT mean
gene CT mean
18
Gene expression rates were then calculated by using the negative control as a reference according to the formula 
(Equation 2):
=




18S rRNA was selected based on the lowest regulation in response to BMP-7 stimulation when compared to 
other reference genes that were tested, i.e. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH), Hypoxanthine 
phosphoribosyl transferase (HPRT), and 60S ribosomal protein L13 (RPL13).
Gene Accession number Primer sequence Forward Primer sequence Reverse Efficiency
18S NM_022551 CGGAAAATAGCCTTTGCCATC AGTTCTCCCGCCCTCTTGGT 1.79
BMPR-Ia NM_004329.2 TGCTGGACGAAAGCCTGAAC TTCCACGATCCCTCCTGTGA 1.78
BMPR-Ib NM_001203.2 ATGCCACCACCATTGTCCAG GTGACCACAGGCAACCCAGA 2.05
ActR-I NM_001111067.2 GTCGGGAAAGGCAGGTATGG TCCGTTTCCCTGAACCATGA 1.93
BMPR-II NM_001204 GCTCTTGCCGTCTTGCTCAT GGCGCACCAGTCTATTTCCA 1.93
ActR-IIA NM_001278580 TTGCGGGGATTGTCATTTGT GGAGAAGGTGGGGGTGGTC 2.03
ActR-IIB NM_001106 CTGCACTGCTACGCCTCCTG ACACCTGGGGGTTCTCCTCA 1.98
Smad1 NM_005900.2 GAAGCGTTCCATGCCTCCTC GGCATACACCTCCCCTCCAA 1.75
Smad4 NM_005359 TCCCAACATTCCTGTGGCTTC CTGCTGCTGTCCTGGCTGA 2.00
Smad5 NM_001001420.1 TTCCACCAGCCCAACAACAC GGCAGGAGGAGGCGTATCAG 1.91
Smad8/9 NM_001127217 ACACCACCCCTGCCTTATCA CCTGGAATGTCTCCCCAACTC 1.81
ID1 NM_181353 GCTGCTCTACGACATGAACG CCAACTGAAGGTCCCTGATG 1.87
OC NM_199173.4 TGAGAGCCCTCACACTCCTC CGCCTGGGTCTCTTC ACT AC 1.78
Col-IA1 NM_000088.3 TGACCTCAAGATGTGCCACT ACCAGACATGCCTCTTGTCC 1.92
Col-IIA1 NM_033150.2 CGCACCTGCAGAGACCTGAA TCTTCTTGGGAACGTTTGCTGG 1.87
Runx2 NR_103532 GCCCCCAAACAGTATCTTGA GCCTGAAGTGAGGTTTTAGGC 1.86
Aggrecan NM_001135.3 CCAGTGCACAGAGGGGTTTG TCCGAGGGTGCCGTGAG 1.89
Mohawk NM_173576.2 TGGTTTGCTAATGCAAGACG CCTTCGTTCATGTGGGTTCT 1.85
Osterix NM_001173467.2 CACCCACCTCAGGCTATGCT TGGATGCCTGCCTTGTACCA 2.08
Sox9 NM_000346 GACTCGCCACACTCCTCCTC CTCAGCTCGCCGATGTCCA 1.84
Scleraxis Commercial product. QuantiTect Primer Assay (Qiagen)
Table 2.  Primer Sequences.
Name Species Manufacturer Dilution
GAPDH (14C10) (#2118) Rabbit mAb Cell signaling 1:2000
beta Actin (Clone AC-15) Mouse mAB Sigma Aldrich 1:5000
total Smad1 (#6944) Rabbit mAb Cell signaling 1:1000
p-Smad1/5/8 (#9511) Rabbit mAb Cell signaling 1:1000
p-p44/42 MAPK (Erk1/2) (#9101) Rabbit pAb Cell signaling 1:1000
p-Akt (Ser473) (D9E) XP® Rabbit mAb Cell signaling 1:1000
p-SAPK/JNK (Thr183/Tyr185) (81E11) Rabbit mAb Cell signaling 1:1000
Anti-ACTIVE® p38 (pTGpY) Rabbit pAb Promega 1:1000
IRDye 800CW polyclonal Anti-Rabbit IgG Goat pAb Li-Cor Biosciences 1:15000
IRDye® 680RD anti-Mouse IgG Goat pAb Li-Cor Biosciences 1:15000
Table 3. Antibodies for western blot.
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Western Blotting. Cells were lysed with 1x Laemmli-buffer and stored at − 20 °C until used for Western 
Blot analysis. Proteins were detected by SDS-PAGE (Mini-PROTEAN Tetra Cell, BioRad) and western blotting 
(Trans-Blot® Cell, BioRad) using antibodies for the Smad-pathway: total Smad1 and the combined antibody for 
p-Smad1/5/8, as well as p-p44/42 MAPK (Erk1/2), p-SAPK/JNK, p-Akt and p-p38 for the non-Smad pathways 
in combination with species-specific IRDye®-conjugated secondary antibodies (Table 3). GAPDH and β -Actin 
served as loading controls. Imaging was conducted using the Odyssey imager and LiCor Odyssey software. 
(n = 6). For normalisation the bands of the p-Smad1/5/8 and total Smad1 were normalised to GAPDH (including 
background correction). In a second step the ratio of the normalised p-Smad1/5/8 and normalised total Smad1 
was calculated. The non-Smad signalling proteins were only analysed exemplarily (n = 3 different donors). Bands 
from the protein of interest were normalised to β -Actin or GAPDH and the unstimulated control.
Statistics. The results are given in box plots as median with 25 and 75 percentiles. Statistical analysis was 
done using SPSS 20 (IBM, USA). Depending on the sample size, significant differences were analysed with the 
Mann-Whitney U test for non-parametric data to compare the stimulation groups with the untreated control and 
adjusted with the Bonferroni-Holm correction (n = 6) or with a one-way ANOVA corrected by Dunnett´s test to 
control or BMP-7 treatment (n = 3). Differences were considered significant at the values of p < 0.05.
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